Michaela Gertz Joins Immunicum as CFO

Press Release

31 January 2018

Michaela Gertz Joins Immunicum as CFO

Immunicum AB (publ; Nasdaq Stockholm: IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced that Michaela Gertz will join the company as Chief Financial Officer effective February 1, 2018. Ms. Gertz brings a range of experience in finance and capital raising transactions to Immunicum, including seven years as CFO for PledPharma, a First North-listed drug development company. Lise-Lotte Hallbäck will leave her position as CFO of Immunicum as of today to pursue other interests. She will remain available to the company for a six-month transition period.

"We welcome Michaela to the team and look forward to her contributions based on her background leading financial operations and fund-raising for a biotechnology company," said Carlos de Sousa, CEO of Immunicum. "Lise-Lotte has been instrumental in the growth of Immunicum. We thank her and appreciate her flexibility to remain with us for a transition period."

"I value the opportunity to join Immunicum at a juncture when the company has achieved the transition to the Nasdaq main market and is now funded to continue the progress of ilixadencel through the Phase II clinical trial," added Ms. Gertz. "It is a great moment to join this exciting company. My focus will be on building shareholder value and working with the team to bring our lead program closer to helping cancer patients."

Michaela Gertz most recently was CFO & Investor Relations Manager at PledPharma AB, a drug development company based in Stockholm.  Ms. Gertz was instrumental in PledPharma's IPO in 2011 and subsequent fund-raising efforts. Prior to that, Ms. Gertz spent three years as Head of Investor Relations and Financing at Accelerator Nordic AB. Before joining the life sciences industry, Ms. Gertz worked in finance and private equity at ITP Invest AB and Handelsbanken. She holds a MSc in Business and Economics from Uppsala University including a course of study at the  Katholieke Universiteit in Leuven, Belgium.

The information is such information that Immunicum is obliged to make public pursuant to EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 31 January 2018 at 9.45 am CET.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: +46 709 71 12 53
E-mail: ir@immunicum.com  

Investor and Media Relations EU/US

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com  

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com